Hepatitis C

HCV transmission knowledge varies among opioid-dependent pregnant patients

HCV transmission knowledge varies among opioid-dependent pregnant patients

By

Most opioid-dependent pregnant patients understand that intravenous drug use is a major transmission modality of HCV.

Statins may lower risk of cirrhosis decompensation in HBV and HCV

Statins may lower risk of cirrhosis decompensation in HBV and HCV

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and in patients with alcohol-induced cirrhosis.

AGA Institute releases practice update for managing patients cured of HCV infection

AGA Institute releases practice update for managing patients cured of HCV infection

Patients with chronic HCV infection who have achieved a sustained virologic response with treatment may still be at risk for complications such as hepatocellular carcinoma.

NASEM report aims to eliminate hepatitis B and C by 2030

NASEM report aims to eliminate hepatitis B and C by 2030

By

Aggressive testing, diagnosis, treatment, and prevention methods, such as needle exchange for those who inject drugs, are some of the options that the NASEM explored to target hepatitis elimination.

FDA approves first direct-acting antivirals for pediatric HCV patients

FDA approves first direct-acting antivirals for pediatric HCV patients

By

Harvoni and Sovaldi have been approved for pediatric patients with HCV genotypes.

Oral, direct-acting antivirals effective for hepatitis C virus infection

Oral, direct-acting antivirals effective for hepatitis C virus infection

By

Regimens for the treatment of hepatitis C that included ribavirin had more mild or moderate adverse events than those without.

Pharmacists can help optimize care in patients with hepatitis C virus

Pharmacists can help optimize care in patients with hepatitis C virus

By

Drug-drug interactions are common in patients taking hepatitis C virus medications, and consulting with a pharmacist can be beneficial.

Hepatitis C infection linked to nonhepatic cancers among elderly patients

Hepatitis C infection linked to nonhepatic cancers among elderly patients

HCV infection is associated with cancers such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

HCV patients with diabetes may have increased risk of hepatocellular carcinoma

HCV patients with diabetes may have increased risk of hepatocellular carcinoma

Diabetes could increase the risk of developing hepatocellular carcinoma in patients with hepatitis C.

VA offers hepatitis, HIV screening to veterans who received improper dental care

VA offers hepatitis, HIV screening to veterans who received improper dental care

By

A VA center in Wisconsin is advising veterans to be screened for hepatitis and HIV after receiving care from a dentist who did not follow VA procedures.

Ledipasvir-sofosbuvir treatment safe for kidney recipients with hepatitis C

Ledipasvir-sofosbuvir treatment safe for kidney recipients with hepatitis C

Treatment for 12 or 24 weeks is safe and efficacious for kidney transplant recipients with hepatitis C virus.

Probable interaction identified between hepatitis C treatments

Probable interaction identified between hepatitis C treatments

Researchers identified an interaction between ribavirin with paritaprevir/ritonavir/ombitasvir and dasabuvir.

More than 1 million people treated with new hepatitis C drugs

More than 1 million people treated with new hepatitis C drugs

By

The cost of the new hepatitis C drugs in low- and certain middle-income countries is rapidly declining, according to a WHO study.

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

HBV and HCV coinfection increases non-Hodgkin risk in ART-treated HIV

Patients with HIV receiving antiretroviral treatment have a higher risk of non-Hodgkin's lymphoma with HBV and HCV coinfection.

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

FDA requires black box warning on HCV drugs regarding potential HBV reactivation

By

The FDA issues a warning about the risk of hepatitis B virus reactivation among patients taking direct-acting antivirals to treat hepatitis C infections.

Reducing the duration of hepatitis C therapy may be effective

Reducing the duration of hepatitis C therapy may be effective

By

Shortening the duration of HCV therapy from 12 weeks to 3 weeks could substantially reduce the cost of treatment.

Patients with hepatitis C prefer therapy with sofosbuvir and ribavirin

Patients with hepatitis C prefer therapy with sofosbuvir and ribavirin

In patients with Hepatitis C, Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy.

Hepatitis C virus core antigen testing is a highly accurate diagnostic tool

Hepatitis C virus core antigen testing is a highly accurate diagnostic tool

By

HCVcAg assays with signal amplification have the potential to replace NAT in settings with high HCV prevalence.

New hepatology rotation increases knowledge of liver disease among residents

New hepatology rotation increases knowledge of liver disease among residents

A new hepatology rotation increased the mean comfort level for managing several liver diseases.

Shared drug paraphernalia linked to hep C transmission

Shared drug paraphernalia linked to hep C transmission

In a study, 24% of confiscated drug snorting straws tested positive for human blood.

Direct-acting antivirals in hepatitis C do not reduce hepatocellular carcinoma occurrence

Direct-acting antivirals in hepatitis C do not reduce hepatocellular carcinoma occurrence

By

Patients previously treated for HCC have a high risk of tumor recurrence in the long term.

Epclusa approved to treat chronic hepatitis C

Epclusa approved to treat chronic hepatitis C

The combination drug treats 6 strains of chronic hepatitis C.

Multidisciplinary approach improves outcomes in hepatitis C

Multidisciplinary approach improves outcomes in hepatitis C

By

Patients with hepatitis C who had a multidisciplinary team during treatment had improved outcomes.

Hepatitis C mortality increasing, now leading cause of death among all infectious diseases

Hepatitis C mortality increasing, now leading cause of death among all infectious diseases

By

The number of deaths associated with hepatitis C is higher than the total number of deaths resulting from 60 other infectious diseases.

Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma

Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma

By

Direct-acting antivirals pose challenges in patients with hepatitis C and prior hepatocellular carcinoma

HCV, HIV co-infection linked to increased diabetes risk

HCV, HIV co-infection linked to increased diabetes risk

Treatment guidelines must expand to focus on patients co-infected with both HCV and HIV.

Sustained virological response found at 5 years in low-risk patients with HCV

Sustained virological response found at 5 years in low-risk patients with HCV

Patients with HCV/HIV coinfections had a much higher risk of HCV recurrence.

Signs and symptoms of hepatitis C virus infection

Signs and symptoms of hepatitis C virus infection

Education of high risk populations and regular testing are crucial steps clinicians can take to stem the spread of hepatitis C infection.

CDC works to eliminate HCV transmission in hemodialysis

CDC works to eliminate HCV transmission in hemodialysis

The organization encourages dialysis providers to improve current infection control practices.

Sign Up for Free e-newsletters